SEC For	rm 4 FORM	4	UNITE	) ST/	ATES S	ECURITI	ES	AN	DE	ХСНА	NG	GE CO	OMMI	SSION				
					Washington, D.C. 20549											OMB APPROVAL		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).					MENT OF CHANGES IN BENEFICIAL OWNE Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									HIP	Estim	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5		
transac contrac the pur securit to satis conditio	rchase or sale of	e pursuant to a r written plan for of equity r that is intended we defense																
1. Name and Address of Reporting Person <sup>*</sup> <u>Pieper Steven</u>						2. Issuer Name <b>and</b> Ticker or Trading Symbol Xeris Biopharma Holdings, Inc. [XERS]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify				
(Last) (First) (Middle) C/O XERIS BIOPHARMA HOLDINGS, INC. 1375 WEST FULTON STREET, SUITE 1300						3. Date of Earliest Transaction (Month/Day/Year) 11/22/2024								below)		lemai	below)	- <b>-</b> - <b>- -</b>
(Street) CHICAC (City)		tate)	_ 4. If Am	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	<ul> <li>6. Individual or Joint/Group Filing (Check Applicable Line)</li> <li>Form filed by One Reporting Person</li> <li>Form filed by More than One Reporting Person</li> </ul>						
		Tat	ole I - Nor	-Deriv	vative Se	curities Ac	qui	red,	Disp	osed o	of, o	r Ben	ficially	y Owned				
······································				2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transacti Code (Ins 8)		action Disposed		ities Acquired (A) d Of (D) (Instr. 3, 4		5. Amou Securitie Benefici Owned F Reporte	es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
								Code V		Amount		(A) or (D) Price		Transaction(s) (Instr. 3 and 4)				(1150.4)
Common Stock 11/22								М		19,48	3	A	\$1.55	1,44	1,820		D	
						urities Acq ls, warrants								Owned				
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Dat urity or Exercise (Month/Day/Year) if any			Date,	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired	Exp	6. Date Exercisable and Expiration Date (Month/Day/Year) (Instr. 3 and 4 Derivative Sec.					ecurity	Derivative der Security Sec		5	10. Ownership Form: Direct (D) or Indirect	Beneficia Ownershi

(Instr. 3)	Price of Derivative Security	(monunday) rear)	(Month/Day/Year)	8) Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			urities uired or oosed 0) (Instr.	(month/bay)		Derivative Security (Instr. 3 and 4)		(Instr. 5)	Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
				Code	v			Date Exercisable	Expiration Date	Amoun or Numbe of Title Shares					
Stock Option (Right to Buy)	\$1.55	11/22/2024		М			16,843	(1)	02/04/2027	Common Stock	16,843	\$0	0	D	
Stock Option (Right to Buy)	\$1.55	11/22/2024		М			2,640	(2)	06/12/2027	Common Stock	2,640	\$0	0	D	

Explanation of Responses:

1. The reporting person received the stock options on February 7, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. The options vested in four equal installments on February 2018, 2019, 2021, and 2021.

2. The reporting person received the stock options on June 12, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. The options vested in four equal installments on June 2018, 2019, 2021, and 2021.

Remarks:

Chief Financial Officer

/s/ Beth Hecht, as Attorney-in-Fact

11/26/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.